title: [Activated C protein resistance manifested by cutaneous necrosis after interferon alpha injection: case report].
abstract: BACKGROUND
  Cutaneous necrosis occurring in the course of treatment by alpha interferon is an uncommon side-effect. Its physiopathologic mechanism remains obscure. A local thrombotic action of interferon has been suggested to explain its occurrence.
  
  
  METHODS
  A 64-year-old male patient with human immunodeficiency virus-related cutaneous Kaposi's sarcoma presented cutaneous necrosis after a 9-month treatment by interferon alpha, while his resistance to activated protein C had already been demonstrated. To our knowledge, this is the first case ever described regarding the association of interferon-induced cutaneous necrosis with activated protein C resistance.
  
  
  CONCLUSIONS
  This suggests that in case of interferon treatment-induced cutaneous necrosis coagulation disorders should be investigated and questions the existence of a particular "pro-coagulant profile" facilitating this side effect.
authors.affiliation: Service de médecine interne A, centre hospitalier Poissy-Saint-Germain, Saint-Germain-en-Laye, France.
authors.forename: F
authors.initials: F
authors.lastname: Plurien
authors.forename: Z
authors.initials: Z
authors.lastname: Le Lostec
authors.forename: C
authors.initials: C
authors.lastname: Pauwels
authors.forename: Y
authors.initials: Y
authors.lastname: Welker
authors.forename: C
authors.initials: C
authors.lastname: Glaser
authors.forename: P
authors.initials: P
authors.lastname: de Mazancourt
authors.forename: J Y
authors.initials: JY
authors.lastname: Peltier
authors.forename: P
authors.initials: P
authors.lastname: Mornet
mesh_terms: D020016:Activated Protein C Resistance / Q000097:blood / Q000150:complications* / Q000175:diagnosis*; D000970:Antineoplastic Agents / Q000009:adverse effects*; D001706:Biopsy; D003875:Drug Eruptions / Q000209:etiology* / Q000473:pathology; D015658:HIV Infections / Q000150:complications; D006801:Humans; D007279:Injections, Subcutaneous; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000009:adverse effects*; D008297:Male; D008875:Middle Aged; D009336:Necrosis; D011994:Recombinant Proteins; D012514:Sarcoma, Kaposi / Q000628:therapy / Q000821:virology; D012878:Skin Neoplasms / Q000628:therapy / Q000821:virology; D013997:Time Factors
chemical_list: D000970:Antineoplastic Agents; D000077190:Interferon alpha-2; D016898:Interferon-alpha; D011994:Recombinant Proteins